Invest in the orthopedics of the future

Monogram is offering preferred Series-A shares in a Reg-A public offering. Learn more about how you can invest and support our technology here.

Learn More

Join us in making this future a reality

Monogram is offering up to preferred series-A shares in this offering to help fund the development and commercialization of our implants, robotics and software.

as of today, we’ve raised

$4,648,492

$7,000,000

Series A

The minimum raise in this offering is $2,750,000. Management estimates the minimum amount required to reach FDA approval to be approximately $7 million.


For an overview of our development plan and strategic business initiatives please watch this quick 5-minute presentation here.

We anticipate being able to start delivering our surgical robots for insertion of generic implants within four years of the close of this offering, assuming no clinical data requests from the FDA.

  • $18 bn

    Monogram’s first target markets will be the hip and knee replacement market which is over $18bn combined.

    THE MAJORITY OF THE MARKET IS IMPLANT SALES, WHICH IS WHY MONOGRAM HAS FOCUSED ON INNOVATING THE IMPLANT.
  • 100%

    After investing over $225M in 3D printing Styker indicated 100% of their hip cups will be 3D printed. This is getting more efficient than conventional manufacturing. Monogram is developing implants for this future.

    “ADDITIVE MANUFACTURING IS THE FUTURE.” KEVIN LOBO, STRYKER CEO
  • 969,000

    51% of primary hip and knee joint replacement surgeries will be performed in an outpatient setting by 2026. The industry is rapidly shifting to force efficiency on large suppliers. Monogram is built on efficiency.

    WE DO NOT BELIEVE HIGH VOLUME HOSPITALS WITH INVENTORY ON CONSIGNMENT IS THE FUTURE
  • 9.7 months

    The average implant sits on the shelf for 9.7 months before getting sold. This inefficiency costs the large companies billions of dollars in

    Saves $3,000 per surgery on average by reducing the amount of inventory you need on hand.

An Optimized Workflow Focused on Improving Patient Lives

  • A good plan starts with good data

    High resolution CT Scan

    Monogram uses 0.6mm slice thicknesses to create a unique 3 dimensional patient model. This model will drive the planning and intra-operative visualization of the surgical site. A good plan always starts with good data.

  • Personalizing your care for your unique needs

    Surgeon planning and execution

    We believe that technology should be assistive and collaborative. We create an optimized plan but we rely on the surgeon to approve and adapt as they see fit. With technology it is easier to execute a well designed, data-driven plan than ever before.

  • Recovery starts first

    Leveraging natural fixation

    Monogram believes that robotically prepared uncemented press-fit implants are the future. As long-life materials continue to improve and younger and more active patients seek treatment, smaller implants that rely on natural long-term fixation will see increased use.

Leveraging the Past to Create the Implants of the Future

Implants Reimagined

Monogram estimates that implant sales account for approximately 85% of the total addressable $18BN market for hips and knees. Rather than derive fixation through a central keel, Monogram’s implant is designed to derive fixation at the extremities, where the bone is most dense and osseointegration most active.

In collaboration with the University of Nebraska Medical Center which specializes in testing tibial components, Monogram tested their first design concept. The performance against the Stryker Triathlon, which has been implanted in over 2 million patients worldwide, was positive in certain areas. Monogram believes that fixation derived at the extremities of the implant will prove clinically superior over time.

Monogram has conducted an FTO and filed provisional patents on it’s knee and hip implant designs.

Developmental Milestones

Monogram is building the future of orthopedics one step at a time.

  • 1st

    Foundational patent filed

    2017

  • 634%

    improved hip micromotion from UCLA Ortho Lab testing

    2018

  • 5

    Additional filed patents

    2019

  • 72%

    improved tibial drift from UNMC testing

    2019

SeedInvest

Monogram is accepting investments to participate in their series-A via SeedInvest which accepts <1% of applications.

invest now on seedinvest

$4,648,492 MILLION RAISED

$7M CURRENT INVESTMENT ROUND

  • $1,000 minimum investment
  • 532 Unique Investors
  • $4990 Avg Investment
  • $4 Share Price